Related Experiment Video
Updated: Mar 7, 2026
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
SRF and SHRM in nAMD: Retrospective Analysis of Visual Prognosis
Weizhen Wu1, Huiling Guo1, Luping Wang1
1Author affiliations:Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Objective:
This study aimed to investigate the correlation between subretinal fluid (SRF) and subretinal hyperreflective material (SHRM) with visual prognosis in neovascular age related macular degeneration (nAMD).
Methods:
A retrospective analysis was conducted on 60 nAMD patients diagnosed at our ophthalmology department from March 2017 to December 2024. All patients received intravitreal anti-vascular endothelial growth factor (VEGF) injections monthly for the first 3 months, followed by pro re nata (PRN) treatment for the subsequent 9 months. Quantitative measurements of SRF and SHRM (height and width on OCT) were collected, along with patient demographics, best corrected visual acuity (BCVA), and central foveal thickness (CMT).
Results:
After 12 months of treatment, BCVA, CMT, and SRF parameters significantly improved (P < 0.05). The visual improvement group showed superior reductions in SRF and SHRM height compared to the nonimprovement group (P < 0.05). Greater baseline SRF thickness (>180 μm) was significantly associated with better final visual acuity (P = 0.034), while baseline SHRM presence correlated with worse final BCVA and CMT (P < 0.05). These findings indicate that SRF serves as a favorable prognostic indicator, whereas SHRM is a key predictor of poor visual outcomes (P = 0.001).
Discussion:
SRF and SHRM morphological features are linked to nAMD treatment response. SRF thickness positively correlates with visual improvement, serving as a prognostic indicator. Persistent SHRM, however, is associated with fibrotic components that may impair retinal function, making it a key parameter for poor outcomes. These findings align with prior studies, highlighting the importance of quantitative SRF and SHRM assessment in predicting treatment response.
Conclusion:
SRF and SHRM are clinically significant biomarkers in nAMD treatment, effectively predicting visual prognosis and guiding individualized therapeutic strategies. Their quantitative evaluation may aid in optimizing treatment tolerance strategies and improving real world clinical outcomes.
